Jan Boren

Head of Department

Institute of Medicine

Mail

jan.boren@wlab.gu.se

Visiting address

Medicinaregatan 3, plan 5

41390 Göteborg

Postal address

Box 428

40530 Göteborg

Professor

Department of Molecular and Clinical Medicine

Telephone

+46 31-342 29 49

+46 733-76 42 64

Mail

jan.boren@wlab.gu.se

Visiting address

Wallenberglab, Bruna stråket 16, SU/S

41345 Göteborg

Postal address

Wallenberglab, Bruna stråket 16, SU/S

41345 Göteborg

About Jan Boren

Professor and Head of the Institute of Medicine, Sahlgrenska Academy at University Av�԰�

Jan Borén is Professor and Head of the Institute of Medicine, Sahlgrenska Academy at University Av�԰�, and physician at the Department of Clinical Chemistry at the Sahlgrenska University Hospital. He obtained his medical degree at the University Av�԰�, where he also completed his PhD. His main research interest is lipid metabolism and he has focused to understand the consequences of and underlying mechanisms that lead to lipid accumulation in the liver, arterial wall and heart, with the goal of translating this knowledge into effective treatment.

His research program is translational and involves both in vitro and in vivo studies, including pathophysiological studies and mouse models, and kinetic studies in carefully phenotyped human volunteers. He is a member of the Royal Society of Arts and Av�԰�s in Gothenburg, and has awarded numerous honours, including the Göran Gustafsson’s Prize in Medicine from the Royal Academy of Av�԰�s, Dr. Eric K Fernström Foundation’s Research Award, and Irvine H. Page Atherosclerosis Research Award. He serves as Vice-President of the European Atherosclerosis Society (EAS), and is Editorial Board Member for Arteriosclerosis, Thrombosis, and Vascular Biology, Section editor for BBA – Molecular and Cell Biology of Lipids and co-Editor of Atherosclerosis.

Education & Degrees

1999 Associate Professor (docent) in Molecular Medicine, University Av�԰�
1994–1998 Research Fellow and Staff Research Investigator, Gladstone Institute of Cardiovascular Disease, Univ. of California San Francisco, San Francisco, CA
1992 PhD, Department of Medical Biochemistry, University Av�԰�, Sweden
1988 MD, University Av�԰�, Gothenburg, Sweden

Distinctions, Scholarships and Awards (selected)

2013– Member, Royal Society of Arts and Av�԰�s in Gothenburg
2004 Göran Gustafsson’s Prize in Medicine from the Royal Academy of Av�԰�s
2004 The Mejlan (Meilahti) Award, Biomedicum, Helsinki, Finland
2000 Dr. Eric K Fernström Foundation’s Prize to Young Swedish Scientists
1999–2001 Junior Grant for “Young Promising Investigators” from Swedish Foundation for Strategic Research (SSF)
1997 Irvine H. Page Atherosclerosis Research Awards for Young Investigators,
American Heart Association, 70th Scientific Sessions
1994–97 Howard Hughes Medical Institute Postdoctoral Fellowship for Physicians
1994 Fulbright Award for Advanced Studies in Biochemistry

National and International Assignments of Importance (selected)

2017– Vice-President European Atherosclerosis Society
2007– Chairman, Dept. of Molecular and Clinical Medicine, Institute of Medicine, University Av�԰�
2006–2012 Director, Strategic Research Center, Sahlgrenska Center for Cardiovascular and Metabolic Research
2005–2017 Treasurer European Atherosclerosis Society
2000–2006 Director, Wallenberg Laboratory for Cardiovascular and Metabolic Research, University Av�԰�

Main Research

CAUSES AND CONSEQUENCES OF CARDIOMETABOLIC DISEASES
Obesity is a well-known risk factor for the development of type 2 diabetes (T2D) and cardiovascular disease (CVD). Importantly, obesity is not only associated with lipid accumulation in adipose tissue, but also in non-adipose tissues. This ectopic lipid accumulation is now recognized as an important link between obesity and its comorbidities. It is not clear how ectopic lipid accumulation induces cellular dysfunction, but elucidation of the underlying mechanisms is important to identify novel therapeutic targets. The overall aim for our research group is to understand the underlying mechanisms that lead to, and consequences of, lipid accumulation in the liver, arterial wall and heart, with the goal of translating this knowledge into effective diagnosis, prevention and treatment.

Fatty liver is linked to increased CVD morbidity and mortality
Non-alcoholic fatty liver disease (NAFLD) is defined as hepatic fat accumulation that exceeds 5% of liver weight in individuals who do not consume significant amounts of alcohol. In the past 2–3 decades, we have seen a marked increase in NAFLD, and it is now the most common cause of chronic liver disease in western countries. Approximately 25–30% of adults have NAFLD, and its prevalence increases to 70–90% among adults with obesity or type 2 diabetes. Although NAFLD may progress to severe liver diseases the most common cause of death in patients with NAFLD is CVD. This is – at least partly – explained by the fact that NAFLD associates with an atherogenic dyslipidemia characterized by increased triglycerides, low high-density lipoproteins (HDL), accumulation of small dense low-density lipoproteins (LDL) and postprandial hyperlipidemia (i.e., increased blood lipids following a meal). Our laboratory has made significant contributions to the current understanding of this harmful dyslipidemia. Specifically, we have shown that: (1) the different components of the dyslipidemia are metabolically linked; (2) a central pathophysiological feature is hepatic fat accumulation, which induces hepatic overproduction of large triglyceride-rich very low-density lipoprotein (VLDL1); (3) the impaired removal of triglyceride-rich lipoproteins (TRLs) induces postprandial hyperlipidemia and accumulation of atherogenic TRL remnants; (4) the impaired removal of TRLs associates with increased plasma concentration of apoC-III (Figure 1); and (5) insulin fails to suppress VLDL1 secretion in subjects with high liver fat.

Retention of atherogenic lipoproteins and their role in atherogenesis
Atherogenesis is initiated by subendothelial accumulation of atherogenic lipoproteins. Lipoprotein retention only occurs in specific vascular areas and is mediated by artery wall proteoglycans in the innermost layer of the artery (the arterial intima). We identified the sequence in apolipoprotein B (apoB, the major protein component of low density lipoproteins [LDL]) that binds to the artery wall proteoglycans and showed a causal relationship between lipoprotein–proteoglycan interactions and development of atherosclerosis. These studies experimentally proved that LDL is causatively linked to atherogenesis and that subendothelial retention of atherogenic apoB-containing lipoproteins is an early key pathogenic event in atherosclerosis. We have further shown that intimal hyperplasia functions as a sink for atherogenic lipoproteins and thus accelerates atherogenesis. Retained and aggregated lipoproteins provoke a series of local biological responses that eventually include maladaptive cellular responses in the arterial wall that accelerate lipoprotein retention and other features of plaque development.

Lipid accumulation in the heart causes cardiac dysfunction
We and others have shown that lipid accumulation in the heart associates with cardiac dysfunction and heart failure in humans. Cardiac fat accumulation has also been proposed to contribute to the high mortality following myocardial infarction in subjects with type 2 diabetes. We recently identified a novel mechanism for lipid accumulation in ischemic hearts and showed that this lipid accumulation resulted in impaired heart function. Specifically, we showed that (1) the very low density lipoprotein receptor (VLDLr) is highly upregulated in hypoxic cardiomyocytes and in human and mouse ischemic hearts causing a detrimental lipid accumulation; and that (2) VLDLr deficiency in mice results in increased survival and reduced infarct area following a myocardial infarction. These findings show that cardiac lipid accumulation results in increased vulnerability to ischemia, and emphasize the importance of identifying the lipids and molecular mechanisms that induce these destructive responses.

Group Members

Staff scientist

Liliana Håversen, PhD
Linda Andersson, PhD
Malin Lindbom, PhD
Mikael Rutberg, PhD

Postdoctoral Fellow

Martina Klevstig, PhD

PhD Student

Elias Björnson
Matias Ekstrand

Research Associate

Eva Hedman Sabler
Maria Heyden
Kristina Skålen
Elin Stenfeldt

Guest Professor

Kevin Williams, MD, PhD

Key Publications

Mardinoglu A, Björnson E, Zhang C, Klevstig M, Ståhlman M, Adiels M, Hakkarainen A, Lundblom N, Kilicarslan M, Hallström BM, Lundbom J, Barrett PHR, Watts GF, Serlie M, Uhlén M, Nielsen J, Smith U, Marschall HU, Taskinen MR, Borén J. Mol Syst Biol. 13(3):916. (2017)
Lee S, Zhang C, Kilicarslan M, Piening BD, Bjornson E, Hallström BM, Groen Ak, Ferrannini E, Laakso M, Snyder M, Blüher M, Uhlén M, Nielsen J, Smith U, Serlie M, Borén J, Mardinoglu A. Cell Metabol. 24(1):172-84 (2016)
Borén J, Watts GF, Adiels M, Söderlund S, Chan D, Hakkarainen A, Lundbom N, Matikainen N, Kahri J, Vergès B, Barrett PH, Taskinen MR. Arterioscler Thromb Vasc Biol. 35(10):2218-24. (2015)
Levin MC, Jirholt P, Wramstedt A, Johansson ME, Gustafsson Trajkovska M, Lundberg A, Ståhlman M, Fogelstrand P, Brisslert M, Fogelstrand L, Yan ZQ, Hansson G, Björkbacka H, Olofsson SO and Borén J. Circ Res. 109:1210-8. (2011)
Perman J, Boström P. Lindbom M, Ståhlman M, Hägg D, Lindskog H, Mattsson Hultén L, Jeppsson A, Petursson P, Herlitz J, Olivecrona G, Strickland DK, Ekroos K, Olofsson S-O, Borén J. J Clin Invest. 121:2625-40. (2011)
Boström P, Rutberg M, Andersson L, Perman J, Lindberg U, Johansson BR, Fernades-Rodriges J, Ericsson J, Nilsson T, Borén J, Olofsson S-O. Nat Cell Biol. 9:1286–93 (2007)
Gustafsson M, Levin M, Skålén K, Perman J, Fridén V, Jirholt P, Olofsson, SO, Fazio S, Linton MF, Semenkovich CF, Olivecrona G, Borén J. Circ Res. 101:777–83. (2007)
Skålen K, Gustafsson M, Rydberg EK, Hulten L.M, Wiklund O, Innerarity TL, Borén J. Nature. 417:750-754 (2002)
Borén J, Olin K, Lee I, Chait A, Wight T.N, Innerarity TL. J Clin Invest. 101:2658–2664. (1998)
Borén J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. J Clin Invest. 101:1084–1093. (1998)

Av�԰�